Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. - Wikidata - wikimedia - TriplyDB

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.

http://www.wikidata.org/entity/Q37632159

about

Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG.Development of a novel anti-human aspartyl-(asparaginyl) β-hydroxylase monoclonal antibody with diagnostic and therapeutic potential.Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer Current controversies in the management of metastatic colorectal cancer.The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.A Flow Cytometry-Based Cytotoxicity Assay for the Assessment of Human NK Cell Activity.Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.IgG Glycome in Colorectal Cancer.Redox control of cancer cell destruction.

P2860

Q30390233-84D91D1E-BE12-427F-9B59-57ECA91666BE Q33599455-A8F8FD5A-E9EA-43CD-A0EC-A5FF61F3BDF8 Q33647681-ABE9A8E4-0A6C-40D0-877E-4FE315E20BEC Q36213066-57F27998-3576-4B51-B6D2-0D55145EA18E Q37138970-5E039F61-2B07-43E7-8162-F840F410C86F Q38538213-E847C706-49E2-4102-BD06-E8B800DD12D7 Q38670431-08AE35FE-FB55-4AEE-AE42-28987835FB4E Q38694446-8D5E7816-4D20-49F4-81EB-558E6CED64E9 Q49724715-356EAAB0-F3E2-49D0-8325-E823F4796488 Q50856757-120FD8D4-E2E9-4EDE-8FCC-3F3DF7AE164E Q51748168-F4F04E3D-CEB3-419E-9C9F-A93E71D52377

P2860

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.

http://www.wikidata.org/entity/Q37632159

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Glyco-engineered anti-EGFR mAb ...... irrespective of chemotherapy.

@en

Glyco-engineered anti-EGFR mAb ...... irrespective of chemotherapy.

@nl

type

label

Glyco-engineered anti-EGFR mAb ...... irrespective of chemotherapy.

@en

Glyco-engineered anti-EGFR mAb ...... irrespective of chemotherapy.

@nl

prefLabel

Glyco-engineered anti-EGFR mAb ...... irrespective of chemotherapy.

@en

Glyco-engineered anti-EGFR mAb ...... irrespective of chemotherapy.

@nl

P1433

Q37632159-6E80C274-D116-4C45-A461-512DB493DBF8

P1476

Q37632159-EDF677C1-AD47-4026-AEC4-3B879D8E2D83

P2093

Q37632159-0E9BE7DC-F8B8-4AA1-AE65-33A648C7963C

Q37632159-1052A694-1758-4CA0-89AD-6977ED56581D

Q37632159-1EEFAD2E-4C20-456C-BC78-6AEF4C43E17D

Q37632159-2EE8A519-FFD0-4734-8AE9-3562B175BDB7

Q37632159-38967BC8-840B-402F-A64D-44C9B70608DF

Q37632159-44092C77-C645-491C-9D49-4BDBB3FB806B

Q37632159-58D91326-F831-4303-BAB9-5F47D6FA4CB4

Q37632159-5990891A-CA5A-4C16-925E-243E5FA74056

Q37632159-69E0007A-BDC5-40DF-9199-0956A3C049E6

Q37632159-8C4162F0-039B-4726-9CC4-16A2A00410A3

P2860

Q37632159-053415AF-CC69-4365-9DB1-5AD5642DD0C9

Q37632159-061C69BF-9473-427B-8FAD-805E70458D71

Q37632159-087B1E5D-0EFE-4071-8B14-B6A280376F9C

Q37632159-0BD57CC1-60B2-4115-B5EC-183EB70337EF

Q37632159-2BE4FBD7-017D-49A8-9883-364BCB5E12ED

Q37632159-316F618B-7864-4296-B2AB-3C986320DF6C

Q37632159-32D61E72-7F5B-42B1-9517-50FCD3FC1241

Q37632159-33B332E7-BF55-44A1-B882-38F525D18FBB

Q37632159-373AF5F1-6E5B-4FB2-8343-37E5D03B43FD

Q37632159-3B5256A0-87F5-4A36-A5FB-5522FDC36A95

P2888

Q37632159-74EFA0E8-D23E-41E9-B88C-4139D7AB169D

P304

Q37632159-E89728AC-7AE9-40B2-9BE1-87A727878CDC

P31

Q37632159-09FF327C-F1AD-49D0-801D-3158376EC2C9

P356

Q37632159-8049FF82-359E-4D9F-A76C-215AC5AEBB04

P407

Q37632159-BB5E9694-5D2C-4ED8-AC51-1B5536357A2D

P433

Q37632159-5C84A851-4394-4268-98EE-2D72AFFC54FB

P478

Q37632159-AC0FE856-81E1-442E-824E-7AD69694AF79

P50

Q37632159-33300A0C-B73E-4DB7-B03E-7BA800AFC5E3

Q37632159-74EE7D1E-DC8C-4CDE-B8B4-8133760B7CCF

Q37632159-FB458D72-B281-4F8A-9E50-C746CE6A367E

P577

Q37632159-CC4C6067-81F1-444A-BF3E-37B48A1A6AFC

P5875

Q37632159-7FCBAAEF-3C49-4920-9424-D6C4B5A4E165

P6179

Q37632159-2F61BD42-9979-4F11-8536-A25F5FB24704

P698

Q37632159-2DA0BDE2-1F81-4DB2-B018-58B1CDECDBC6

P921

Q37632159-281CD63A-293E-4FFB-A928-189240045E87

Q37632159-97886364-1B4E-4DD7-AC0E-46DBA7FA5420

P932

Q37632159-B416D67D-76A4-4C13-9A6D-29120E9851D8

P356

P1433

British Journal of Cancer

P1476

Glyco-engineered anti-EGFR mAb ...... irrespective of chemotherapy.

@en

P2093

A Belousov

http://www.w3.org/2001/XMLSchema#string

A Etuk

http://www.w3.org/2001/XMLSchema#string

A Passioukov

http://www.w3.org/2001/XMLSchema#string

B S Choi

http://www.w3.org/2001/XMLSchema#string

C Gerdes

http://www.w3.org/2001/XMLSchema#string

C Peña-Murillo

http://www.w3.org/2001/XMLSchema#string

D E Oppenheim

http://www.w3.org/2001/XMLSchema#string

E Amofah

http://www.w3.org/2001/XMLSchema#string

L McLaughlin

http://www.w3.org/2001/XMLSchema#string

P Ross

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer; a biological approach. I. The processes of control

Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

Natural killer cells in human cancer: from biological functions to clinical applications

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

P2888

P304

1221-1227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.35

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Farzin Farzaneh

Roberto Spreafico

David F G Malone

P577

2014-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260094148

http://www.w3.org/2001/XMLSchema#string

P6179

1039529758

http://www.w3.org/2001/XMLSchema#string

P698

24496456

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3950873

http://www.w3.org/2001/XMLSchema#string